XYLONOR Spray Solution 15% w/w

País: Australia

Idioma: inglés

Fuente: Department of Health (Therapeutic Goods Administration)

Ingredientes activos:

lidocaine, Quantity: 150 mg/g; cetrimide, Quantity: 1.5 mg/g

Disponible desde:

Specialites Septodont Pty Ltd

Designación común internacional (DCI):

Cetrimide,lidocaine (lignocaine)

formulario farmacéutico:

Spray, solution

Composición:

Excipient Ingredients: saccharin; Spearmint oil; dipropylene glycol; ethanol

Vía de administración:

Topical, Buccal

Unidades en paquete:

1 x 36G

tipo de receta:

(S4) Prescription Only Medicine

indicaciones terapéuticas:

INDICATIONS AS AT 1 JANUARY 1991: Topical anaesthesia of the mucous membrane of the buccal cavity, before: Nerve block or local anaesthetic injection, Extraction of mobile, deciduous or permanent teeth, Adjustment and fitting of crowns and bridges, Or adjustmentof bands in orthodontic treatments; Lancing of sub mucosal abscesses, Scaling.

Resumen del producto:

Visual Identification: Clear solution.; Container Type: Bottle; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius

Estado de Autorización:

Registered

Fecha de autorización:

1994-07-13

Ficha técnica

1
AUSTRALIAN PRODUCT INFORMATION – XYLONOR (LIDOCAINE
(LIGNOCAINE), CETRIMIDE) TOPICAL ANAESTHETIC
1
NAME OF THE MEDICINE
Lidocaine (lignocaine), cetrimide
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
XYLONOR SPRAY
Lidocaine (lignocaine) base
............................................... 15 g
Cetrimide
................................................................................
0.15 g
Excipient q.s. ad.
.................................................................. 100
g
Contains Saccharin and Alcohol (ethanol)
XYLONOR GEL
Lidocaine (lignocaine) base
................................................. 5 g
Cetrimide
................................................................................
0.15 g
Excipient q.s. ad.
................................................................. 100
mL
Contains Saccharin
XYLONOR PELLETS
Lidocaine (lignocaine) base
................................................. 5 g
Cetrimide
................................................................................
0.15 g
Excipient q.s. ad.
................................................................. 100
mL
Contains Saccharin
One impregnated pellet contains approximately 100 mg of the above
solution.
For the full list of excipients, see Section 6.1 List of excipients.
XYLONOR is an association of:
•
a powerful anaesthetic, Lidocaine (lignocaine),
a bactericide, Cetrimide, in a non-irritant, water-soluble excipient.
3
PHARMACEUTICAL FORM
XYLONOR GEL: clear gel
XYLONOR PELLETS: dressing, medicated; pellet soaked in solution
XYLONOR SPRAY: Spray with clear solution
2
4
CLINICAL PARTICULARS
4.1
T
HERAPEUTIC INDICATIONS
XYLONOR GEL
Topical anaesthesia and disinfection of the mucosa before:
-
injections
-
extraction of mobile, deciduous or permanent teeth
-
extraction of teeth due to pyorrhoea
-
adjusting and fitting of crowns & bridges
-
lancing of abscesses
-
scaling
Prevention of gagging during impression taking.
XYLONOR PELLETS
Topical anaesthesia and disinfection of the mucosa before:
-
injections
-
extraction of mobil